Page last updated: 2024-09-04

isovitexin and malondialdehyde

isovitexin has been researched along with malondialdehyde in 1 studies

Compound Research Comparison

Studies (isovitexin)	Trials (isovitexin)	Recent Studies (post-2010) (isovitexin)	Studies (malondialdehyde)	Trials (malondialdehyde)	Recent Studies (post-2010) (malondialdehyde)
123	0	81	27,849	1,405	13,922

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Liu, S; Wang, J; Zhang, X	1

Other Studies

1 other study(ies) available for isovitexin and malondialdehyde

Article	Year
Isovitexin protects against cisplatin-induced kidney injury in mice through inhibiting inflammatory and oxidative responses. International immunopharmacology, 2020, Volume: 83 Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Apigenin; Blood Urea Nitrogen; Cisplatin; Creatinine; Cytokines; Female; Heme Oxygenase-1; Inflammation; Malondialdehyde; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidative Stress; Reactive Oxygen Species	2020

Article

Year

Isovitexin protects against cisplatin-induced kidney injury in mice through inhibiting inflammatory and oxidative responses.

International immunopharmacology, 2020, Volume: 83

Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Apigenin; Blood Urea Nitrogen; Cisplatin; Creatinine; Cytokines; Female; Heme Oxygenase-1; Inflammation; Malondialdehyde; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidative Stress; Reactive Oxygen Species

2020